Fennec Pharmaceuticals
FENC
49 hedge funds and large institutions have $46.7M invested in Fennec Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
4% more funds holding
Funds holding: 47 → 49 (+2)
0.94% less ownership
Funds ownership: 49.38% → 48.44% (-0.94%)
25% less capital invested
Capital invested by funds: $62.2M → $46.7M (-$15.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$463K |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$302K |
| 3 |
Renaissance Technologies
New York
|
+$204K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$204K |
| 5 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
+$131K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.78M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$178K |
| 3 |
BlackRock
New York
|
-$148K |
| 4 |
Morgan Stanley
New York
|
-$123K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$45.3K |
FENC Hedge Fund Activity: Q1 2019 in Review
49 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q1 2019, worth a combined $46.7M — down 25% from $62.2M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new FENC positions and 2 closed out — a net gain of 2 holders — while 17 added to existing stakes and 11 trimmed.
The largest buyer was Oxford Asset Management, adding an estimated $463K. The largest seller was Opaleye Management, cutting an estimated $1.78M.
- 49 institutional investors held Fennec Pharmaceuticals (FENC) as of Q1 2019, up from 47 in Q4 2018.
- Funds reported $46.7M of Fennec Pharmaceuticals stock for Q1 2019, down 25% quarter-over-quarter.
- 4 funds opened new Fennec Pharmaceuticals positions in Q1 2019 and 2 closed out, a net change of +2 holders.
- The largest Fennec Pharmaceuticals buyer in Q1 2019 was Oxford Asset Management, an estimated $463K added.
- The largest Fennec Pharmaceuticals seller in Q1 2019 was Opaleye Management, an estimated $1.78M sold.
Based on aggregated 13F filings for Q1 2019.